Vicriviroc

CAS : 306296-47-9

Ref. 3D-FV104151

Informations sur le produit

• Nom: Vicriviroc
• Synonymes: (4,6-Dimethyl-5-pyrimidinyl)[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-1-piperidinyl]methanone, 5-({4-[(3S)-4-{(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl}-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine, 5-[4-[4-[2-methoxy-1(R)-[4-(trifluoromethyl)phenyl]ethyl]-3(S)-methylpiperazin-1-yl]-4-methylpiperidin-1-ylcarbonyl]-4,6-dimethylpyrimidine, Methanone, (4,6-dimethyl-5-pyrimidinyl)[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-1-piperidinyl]-, Mk 7690, Piperidine, 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-, Sch-417690, Sch-D, Vicroviroc

Description

Vicriviroc is an HIV protease inhibitor that inhibits HIV replication by binding to the active site of the enzyme, which prevents the destruction of viral proteins necessary for viral replication. Vicriviroc has minimal toxicity, as it is bound to plasma proteins and is not absorbed into cells. It is used in combination with other drugs as part of a regimen for the treatment of HIV-1. Vicriviroc binds to human cytochrome P450 3A4 (CYP3A4) and blocks the metabolism of certain drugs, such as cyclosporin, tacrolimus, and erythromycin. This drug also has been shown to have cardiac effects in patients on long-term therapy with it.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 533.63 g/mol
• Formule: C₂₈H₃₈F₃N₅O₂
• Degré de pureté: Min. 95%